Clinical trial
Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway
NCT00456898 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00456898 |
|---|---|
| Title | Study Evaluating the Potential of DVS SR to Inhibit the CYP2D6 Pathway |
| Official title | A Randomized, Open-Label, 3-Period Crossover Study to Evaluate the Effect of Multiple Doses of DVS SR and Paroxetine on the CYP2D6 Biotransformation of Codeine to Morphine in Healthy Subjects. |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Depressive Disorder, Major, Diabetic Neuropathies, Fibromyalgia, Vasomotor Symptoms |
| Intervention type | Drug |
| Interventions | desvenlafaxine sustained release (DVS SR), Paroxetine, Codeine |
| Enrollment | 40 |
| Start date | Jan 1, 2007 |
| Completion | Mar 1, 2007 |
| First posted | Apr 5, 2007 |
| Last update posted | Dec 28, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: